L
Lisa G. Patel
Researcher at Research Triangle Park
Publications - 6
Citations - 953
Lisa G. Patel is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Ritonavir & Abacavir. The author has an hindex of 5, co-authored 6 publications receiving 923 citations.
Papers
More filters
Journal ArticleDOI
Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662.
Lisa M. Leesnitzer,Derek J. Parks,Randy K. Bledsoe,Jeff E. Cobb,Jon L. Collins,Thomas G. Consler,Roderick G. Davis,Emily A. Hull-Ryde,James M. Lenhard,Lisa G. Patel,Kelli D. Plunket,Jennifer L. Shenk,Julie B. Stimmel,Christina Therapontos,Timothy M. Willson,Steven G. Blanchard +15 more
TL;DR: The selective and irreversible nature of GW9662 treatment, and the observation that activity is maintained in cell culture experiments, suggests that this compound may be a useful tool for elucidation of the role of PPARgamma in biological processes.
Journal ArticleDOI
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
Joseph J. Eron,Patrick Yeni,Joseph C. Gathe,Vicente Estrada,Edwin DeJesus,Schlomo Staszewski,Philip Lackey,Christine Katlama,Benjamin Young,Linda Yau,Denise H. Sutherland-Phillips,Paul Wannamaker,Cindy Vavro,Lisa G. Patel,Jane Yeo,Mark S. Shaefer +15 more
TL;DR: Fosamprenavir-ritonavir twice daily in treatment-naive patients provides similar antiviral efficacy, safety, tolerability, and emergence of resistance as lopinavir-ritis-rit onavir, each in combination with abacvir-lamivudine.
Journal ArticleDOI
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Kathleen Squires,Benjamin Young,Edwin DeJesus,Nicholaos C. Bellos,Daniel Murphy,Henry H. Zhao,Lisa G. Patel,Lisa L. Ross,Paul Wannamaker,Mark S. Shaefer +9 more
TL;DR: ATV in combination with abacavir/lamivudine is a potent and well tolerated regimen in patients who have achieved initial suppression on an induction regimen and represents a viable treatment simplification strategy.
Journal ArticleDOI
Safety and Efficacy of a 36-Week Induction Regimen of Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir in HIV-Infected Patients
Kathleen Squires,Benjamin Young,Edwin DeJesus,Nicholas Bellos,Daniel Murphy,Denise H. Sutherland-Phillips,Henry H. Zhao,Lisa G. Patel,Lisa L. Ross,Paul Wannamaker,Mark S. Shaefer,Aries Study Team +11 more
TL;DR: Induction with ATV/RTV + ABC/3TC once daily provides an efficacious and well-tolerated regimen for the initial treatment of HIV.
Journal ArticleDOI
A study of HIV provider attitudes toward HLA-B 5701 testing in the United States.
TL;DR: It is suggested that HLA-B 5701 testing is easy to use in clinical practice and is a valuable tool to help reduce the risk of developing ABC HSR.